Aisling Capital Research
Investment Thesis
Aisling Capital is a healthcare-dedicated investment firm founded in 2000 and based in New York. The firm's stated mission is to identify and back companies developing and commercializing important, innovative healthcare products, services, and technologies that address unmet medical needs. Aisling positions itself as an active partner rather than a passive check-writer, drawing on its team's combined 150+ years of healthcare industry experience (clinical, operational, and financial) to support portfolio companies with capital and strategic guidance through the full arc of drug and device development, from private financing through commercialization.
Sector Focus
The portfolio is concentrated almost entirely in biopharmaceuticals and life sciences, with recurring emphasis on:
- Oncology and precision/targeted cancer therapeutics
- Neuroscience and CNS disorders (including psychedelics-based mental health treatment)
- Rare and orphan diseases
- Immunotherapy and cell therapy (CAR-T)
- Medical aesthetics and dermatology
- Healthcare services and pharmaceutical outsourcing
The firm does not appear to invest outside of healthcare/life sciences (no consumer, enterprise software, or fintech exposure observed).
Stage Focus
Aisling is unusually stage-agnostic within healthcare. Public materials describe the strategy as spanning seed and venture financings for development-stage companies, small-cap public equity investments (PIPEs and follow-ons in public biopharma), structured debt/royalty transactions, and leveraged buyouts of profitable healthcare enterprises. In practice, recent activity skews toward late private (Series A/B, often very large rounds alongside major life-science investors) and public-market participation in already-listed portfolio companies.
Check Size
Exact check size is not disclosed publicly. Given the firm's $2B+ in committed capital across five funds since 2000 and participation in financings ranging from ~$35M private raises to $300M public offerings, typical single-transaction commitments likely span several million to tens of millions of dollars, with larger allocations reserved for follow-on and public-market positions.
Lead Tendency
Mixed. Aisling frequently participates as one of several life-science-specialist co-investors (e.g., alongside Samsara Biocapital, Catalio Capital, Sofinnova, Novo Holdings) in syndicated private rounds, and also appears as a long-term shareholder adding to positions in public offerings for existing portfolio companies. There is not clear evidence it typically leads or sets terms, so lead tendency is best classified as unknown/both.
Recent Activity
Aisling has been highly active through 2025-2026:
- July 2026: New investor in Claris Bio's $118M Series B (ophthalmology, limbal stem cell deficiency)
- August 2025: Participated in Treeline Biosciences' $200M Series A extension (oncology drug discovery)
- July 2026: Portfolio company Allotera Therapeutics (formerly Wugen) closed a $35M financing to advance off-the-shelf CAR-T therapies
- Multiple 2026 public-market actions across portfolio companies: BridgeBio (two NDA submissions), Compass Pathways (FDA rolling NDA review plus $150M offering and $200M warrant exercise), Monte Rosa Therapeutics ($300M offering), Veradermics (IPO pricing)
Fund status reads as actively deploying, with a steady cadence of both new private investments and continued support of existing public portfolio companies.
Portfolio Highlights
Notable exits/liquidity events: Loxo Oncology (acquired by Eli Lilly), Zeltiq Aesthetics (CoolSculpting, acquired by Allergan), Aimmune Therapeutics (acquired by Nestle Health Science), Quintiles (biopharma outsourcing, later merged to form IQVIA). Active notable holdings include BridgeBio Pharma, Compass Pathways, Biohaven, Harmony Biosciences, Syndax Pharmaceuticals, Marker Therapeutics, Monte Rosa Therapeutics, OnKure Therapeutics, Bicara Therapeutics, and newer private additions Treeline Biosciences and Claris Bio. The firm counts 127+ companies invested since inception per third-party trackers.
Team
- Steven Elms, Managing Partner - co-founded the firm in 2000; former Chase H&Q life sciences investment banker
- Andrew Schiff, MD, Managing Partner - co-founded the firm in 2000; practicing internal medicine physician and Clinical Assistant Professor
- Eric Aguiar, MD, Partner - joined 2016; former partner at Thomas, McNerney and Partners and HealthCare Ventures
- Sunny Reddy, Principal - joined 2019; former Leerink Partners healthcare banker
- Wonpyo Yun, Principal - rejoined 2022; former Investment Director at BridgeBio (a portfolio company)
- Robert Wenzel, CFO/CCO - joined 2008; former VP at Lazard Alternative Investments
- Josh Bilenker, MD, Operating Partner - former CEO of portfolio company Loxo Oncology through its Eli Lilly acquisition
- Scott Braunstein, MD, Operating Partner - currently CEO of Marinus Pharmaceuticals
- Aftab Kherani, MD, Operating Partner - former McKinsey engagement manager and Duke surgery chief resident
Decision Process
Small, senior partnership (two co-founding Managing Partners plus a Partner and two Principals handle deal execution), supplemented by physician Operating Partners who provide clinical/operating diligence. Consistent with a partnership-style decision process rather than a solo GP or large investment committee.
Founder Preferences
Aisling backs experienced healthcare management teams and scientific founders, frequently placing its own physician Operating Partners into CEO or board roles at portfolio companies (e.g., Josh Bilenker at Loxo, Scott Braunstein at Marinus), suggesting a strong preference for hands-on operational involvement alongside capital.
Geographic Focus
Headquartered in New York, NY, with a stated focus on healthcare and life-science companies across the United States, Canada, and Europe.